Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Sales (2024 - 2025)

Prime Medicine's Return on Sales history spans 2 years, with the latest figure at 56.71% for Q4 2025.

  • For Q4 2025, Return on Sales fell 3735.0% year-over-year to 56.71%; the TTM value through Dec 2025 reached 44.22%, up 2144.0%, while the annual FY2025 figure was 44.08%, 2158.0% up from the prior year.
  • Return on Sales reached 56.71% in Q4 2025 per PRME's latest filing, down from 43.13% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 19.37% in Q4 2024 to a low of 367.92% in Q2 2024.